Recent developments include the FDA approval and commercialization transition of VEPPANU, Q3 2026 financial results reporting a net loss, and ongoing corporate updates regarding collaborations and clinical programs.

• Arvinas reported Q3 2026 financial results showing a net loss, with ongoing preparations for VEPPANU commercialization under Rigel's management [N2][N3].
• The FDA approved VEPPANU in Q2 2026 for treatment of ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, marking the first FDA-approved PROTAC protein degrader therapy [N6].
• Arvinas, Pfizer, and Rigel entered into a license agreement in May 2026 granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU, with Rigel responsible for U.S. commercialization [N2].
• Arvinas announced plans to seek out-licensing agreements for additional clinical trials for ARV-806, indicating ongoing pipeline development efforts [N2].
• The company continues to rely on third-party CROs and manufacturers for clinical trials and production, without owning manufacturing facilities [S2].

Arvinas's pioneering PROTAC technology and the FDA approval of VEPPANU position it as an innovator in targeted protein degradation therapies. Strategic collaborations with established pharmaceutical companies provide access to development, manufacturing, and commercialization expertise and resources. The company's strong liquidity supports ongoing research and development activities. Continued progress in clinical trials and successful partnerships could enhance its product pipeline and market presence.

Arvinas faces significant risks from its dependence on collaborators such as Rigel, Pfizer, and Novartis for commercialization and development, limiting its control over key activities. Termination or underperformance by collaborators could delay or halt product development and commercialization. The company operates at a net loss and relies on external funding sources. Competition from larger firms with greater resources and potential challenges in securing future collaborations may impede growth. Reliance on third-party manufacturers and CROs introduces operational risks that could affect timelines and product quality.

Arvinas's moat is based on its proprietary PROTAC technology platform, which enables targeted protein degradation, a novel therapeutic approach. The company has established collaborations with major pharmaceutical companies, granting exclusive rights to certain product candidates, which may limit competition in those areas. Its first FDA-approved PROTAC product, VEPPANU, represents a pioneering therapy in its class. However, the company's reliance on collaborators for development and commercialization, as well as the competitive landscape with larger firms possessing greater resources, presents challenges to sustaining a durable competitive advantage.

• Dependence on Collaborators: Arvinas relies heavily on collaborators like Rigel, Pfizer, and Novartis for development and commercialization. Their discretion over resources and strategic priorities may impact product progress and revenue.
• Competition: The company faces competition from larger pharmaceutical and biotechnology firms with greater financial and operational resources, which may affect market opportunities.
• Operational Risks from Third Parties: Dependence on third-party CROs and manufacturers introduces risks related to quality, compliance, and supply continuity that could delay development or commercialization.
• Financial Risks: Arvinas operates at a net loss and depends on external capital and collaboration revenues to fund operations and development programs.
• Collaboration Termination Risks: Termination of collaboration or license agreements could require additional capital or lead to delays in product development and commercialization.

• Arvinas, Inc. is a biotechnology company focused on developing PROTAC protein degrader therapies.
• The company has collaborations and license agreements with Pfizer, Novartis, and Rigel for development and commercialization of its product candidates.
• Vepdegestrant (VEPPANU) is Arvinas's only FDA-approved product, approved in Q2 2026 for treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
• Arvinas granted Pfizer worldwide co-exclusive rights to develop and commercialize vepdegestrant under a collaboration agreement starting in July 2021.
• In May 2026, Arvinas, Pfizer, and Rigel entered into a license agreement granting Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU.
• Rigel is responsible for commercialization of VEPPANU in the U.S. and has global rights with sublicensing ability outside the U.S., with Arvinas and Pfizer entitled to a percentage of sublicensing revenue.
• Arvinas is dependent on Rigel's performance for commercialization and development of VEPPANU, including funding and execution.
• Arvinas has an out-license agreement with Novartis for luxdegalutamide (ARV-766), which Novartis is responsible for developing and commercializing worldwide.
• Arvinas's collaborations with Pfizer and Genentech for research and development have terminated in 2026 (Genentech in August, Pfizer in October).
• Arvinas relies on third-party contract research organizations (CROs), contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs) for clinical trials and manufacturing.
• The company does not own or operate manufacturing facilities and depends on third parties for drug substance and product manufacturing.
• Arvinas reported a net loss of $53.9 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.82 per share.
• As of September 30, 2026, Arvinas had $88 million in cash and equivalents and $470.4 million in short-term investments, with a current ratio of 8.39 and a cash ratio of 7.98, indicating strong liquidity.
• Annual revenue reported was $262.6 million for the fiscal year ended December 31, 2025.
• Arvinas faces significant competition from companies with greater resources in research, development, manufacturing, clinical trials, regulatory approvals, and marketing.
• The company faces risks related to dependence on collaborators and licensees, including their discretion over resources, potential delays or termination of programs, and intellectual property enforcement.
• Collaborators such as Pfizer, Novartis, and Rigel have significant decision-making authority over development and commercialization of licensed products.
• Termination of collaboration agreements could require Arvinas to seek additional capital or alter development plans.
• Arvinas has incorporated artificial intelligence and machine learning in its drug discovery processes, including its PROTAC Discovery Engine.
• The company announced plans to seek out-licensing agreements for additional clinical trials for ARV-806.
• Arvinas's business model relies heavily on strategic collaborations and licensing arrangements for research, development, and commercialization of its product candidates.